WO2000039280A3 - Leukocyte-derived interferon preparations - Google Patents

Leukocyte-derived interferon preparations Download PDF

Info

Publication number
WO2000039280A3
WO2000039280A3 PCT/US1999/031198 US9931198W WO0039280A3 WO 2000039280 A3 WO2000039280 A3 WO 2000039280A3 US 9931198 W US9931198 W US 9931198W WO 0039280 A3 WO0039280 A3 WO 0039280A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
leukocyte
omega
natural type
interferon preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/031198
Other languages
French (fr)
Other versions
WO2000039280A9 (en
WO2000039280A8 (en
WO2000039280A2 (en
Inventor
Joseph P Morris
Duy Nguyen
James Kappelman
Mead M Mccabe
Michael D Potter
M Reza Ziai
Stephen Feldman
Hipolito Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viragen Inc
Original Assignee
Viragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/224,895 external-priority patent/US6350589B1/en
Priority claimed from US09/229,039 external-priority patent/US6433144B1/en
Application filed by Viragen Inc filed Critical Viragen Inc
Priority to EP99967753A priority Critical patent/EP1140144A4/en
Publication of WO2000039280A2 publication Critical patent/WO2000039280A2/en
Publication of WO2000039280A8 publication Critical patent/WO2000039280A8/en
Anticipated expiration legal-status Critical
Publication of WO2000039280A3 publication Critical patent/WO2000039280A3/en
Publication of WO2000039280A9 publication Critical patent/WO2000039280A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to methods for isolating highly-purified mixtures of natural type I interferons from white blood cells. The invention also relates to highly-purified mixtures of natural type I interferons which resemble natural type interferon in that it includes 9 subtypes, i.e., alpha-1, alpha-2, alpha-5, alpha-7, alpha-8, alpha-10, alpha-14, alpha-21 and omega, giving rise to possibly 20 molecular species, including alpha-1a, alpha-1new, alpha-2a, alpha-2b, alpha-2c, alpha-5, alpha-5LG, alpha-7, alpha-8a, alpha-8c, alpha-10a, alpha-14a, alpha14-b, alpha 14-c, alpha-14LG, alpha-21a, alpha-21b, alpha-21c, omega and omega LG.
PCT/US1999/031198 1998-12-31 1999-12-29 Leukocyte-derived interferon preparations Ceased WO2000039280A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99967753A EP1140144A4 (en) 1998-12-31 1999-12-29 Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/224,895 1998-12-31
US09/224,895 US6350589B1 (en) 1998-12-31 1998-12-31 Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US09/229,039 US6433144B1 (en) 1999-01-12 1999-01-12 Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US09/229,039 1999-01-12

Publications (4)

Publication Number Publication Date
WO2000039280A2 WO2000039280A2 (en) 2000-07-06
WO2000039280A8 WO2000039280A8 (en) 2000-10-19
WO2000039280A3 true WO2000039280A3 (en) 2001-07-19
WO2000039280A9 WO2000039280A9 (en) 2001-08-23

Family

ID=26919102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/031198 Ceased WO2000039280A2 (en) 1998-12-31 1999-12-29 Leukocyte-derived interferon preparations

Country Status (2)

Country Link
EP (1) EP1140144A4 (en)
WO (1) WO2000039280A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727519B2 (en) 2000-11-03 2010-06-01 Intarcia Therapeutics, Inc. Method for treating hepatitis C virus with omega interferon

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822845B1 (en) 2001-03-30 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES
FR2823764B1 (en) 2001-04-24 2003-12-12 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN ALPHA-17 GENE
FR2825716B1 (en) 2001-06-11 2004-09-24 Genodyssee NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES FROM IFN ALPHA 7
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2006212012B2 (en) 2005-02-12 2011-10-13 Swedish Orphan Biovitrum International Ab Methods and uses of antibodies in the purification of interferon
KR101106510B1 (en) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 Two-piece, internal-channel osmotic delivery system flow modulator
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2547990C2 (en) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Fast achievement and/or completion of substantial stable drug delivery
RU2482871C2 (en) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Composition for treating viral diseases in animals
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (en) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Implant installation and extraction systems
KR102574993B1 (en) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (en) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド A method comprising continuous administration of a GLP-1 receptor agonist and co-administration of drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
DE69324671D1 (en) * 1992-02-10 1999-06-02 Interferon Sciences Inc IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD
EP0626448A3 (en) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon
ATE205256T1 (en) * 1994-04-09 2001-09-15 Hoffmann La Roche METHOD FOR PRODUCING ALPHA INTERFERON

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADOLF G. R. ET. AL.: "Purification and characterization of natural human interferon (omega)1:two alternative cleavage sites for the signal peptidase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 16, 5 June 1990 (1990-06-05), pages 9290 - 9295, XP002929489 *
See also references of EP1140144A4 *
SHIRONO H. ET. AL.: "Existence and unique N-terminal sequence of alpha II (omega) interferon in natural leukocyte interferon preparation", BIOCHEM. BIOPHYS. RES. COMM., vol. 168, no. 1, 16 April 1990 (1990-04-16), pages 16 - 21, XP002929488 *
YAN Y. ET. AL.: "Study on the production of human interferon alpha-2b expressed in Escherichia coli", CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 12, no. 1, 1996, pages 25 - 29, XP002929490 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727519B2 (en) 2000-11-03 2010-06-01 Intarcia Therapeutics, Inc. Method for treating hepatitis C virus with omega interferon

Also Published As

Publication number Publication date
EP1140144A2 (en) 2001-10-10
EP1140144A4 (en) 2002-10-30
WO2000039280A8 (en) 2000-10-19
WO2000039280A2 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
WO2000039280A3 (en) Leukocyte-derived interferon preparations
DK1032662T3 (en) Methods and Compositions for Immunomodulation
DK0708772T3 (en) Imidazo [4,5-c] pyridin-4-amines
DE69929313D1 (en) METHOD AND COMPOSITIONS FOR THE ADMINISTRATION OF TAXANES
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
DE69718811D1 (en) METHOD FOR THE QUICK IN-SITU ANALYSIS OF SELECTED COMPONENTS OF HOMOGENEOUS SOLID COMPOSITIONS, IN PARTICULAR PHARMACEUTICAL COMPOSITIONS
TR199701071T2 (en) Compounds and compositions for the delivery of the active substance.
BR9807577A (en) Method to prevent and delay the onset of Alzheimer's disease and its composition
GB9822440D0 (en) Medicaments
EE200100507A (en) Hydroxymatairesinol for cancer prevention
AU2137497A (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
ATE426397T1 (en) COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION
ATE272628T1 (en) SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONES AND ANALOGUES THEREOF, AND USES THEREOF
WO2001068697A3 (en) Methods and compositions for immunoregulation
SE9603725D0 (en) New teatment
WO1999059617A3 (en) Immunoregulator
BRPI0309421A8 (en) METHOD OF PREPARING A FOODSTUFFS AND COMPOSITION TO TREAT OR PREVENT HYPERCHOLESTEROLEMIA
WO1996013498A3 (en) L-erythrosyl nucleosides
ATE226065T1 (en) SOLID INSTANT-RELEASE DOSAGE FORMS AND METHOD FOR THE PRODUCTION THEREOF
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
DE60024967D1 (en) Chaperonin 10 und beta-interferon therapie für multiple sklerose
ATE135917T1 (en) STABILIZED PHARMACEUTICAL COMPOSITION COMPRISING NON-GLYCOZYLATED, REDUCED RECOMBINANT HUMAN IL-2 AND METHOD FOR THE PRODUCTION THEREOF
DE69816808D1 (en) SOMATOSTATIN AGONISTE FOR REDUCING BODY WEIGHT
IL112668A0 (en) 4-amino 6-substituted mycophenolic acid and derivatives thereof, their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AT AU BR CA CH CN DE DK ES FI GB IL IN JP KR MX NO RU SE TR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AT AU BR CA CH CN DE DK ES FI GB IL IN JP KR MX NO RU SE TR

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 27/2000 UNDER (81) ADD "AE, AU, BR, CA, CN, IL, IN, JP, KR, MX, NO, RU, TR"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AT AU BR CA CH CN DE DK ES FI GB IL IN JP KR MX NO RU SE TR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999967753

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1-32, DESCRIPTION, REPLACED BY NEW PAGES 1-33; PAGES 33-39, CLAIMS, REPLACED BY NEW PAGES 34-40; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999967753

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999967753

Country of ref document: EP